Trisubstituted carbocyclic cyclophilin binding compounds and their use
申请人:——
公开号:US20020165275A1
公开(公告)日:2002-11-07
The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.
TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE
申请人:GUILFORD PHARMACEUTICALS INC.
公开号:EP1360173A2
公开(公告)日:2003-11-12
Micropattern retardation element
申请人:Matsunaga Daisaku
公开号:US20070134442A1
公开(公告)日:2007-06-14
The present invention relates to a micropattern retardation element requiring no stretch processing and no extremely high positioning accuracy in cutting films, and the like, and having the retardation region controlled in width of a micron unit, and a producing method therefore. Said micropattern retardation element can be obtained by forming a liquid crystalline or non liquid crystalline polymer thin film layer having photoactive groups, on a substrate, and then, after orientation treatment in a micropattern form, forming a birefringence layer so as to contact with said polymer thin film layer, so that birefringence molecules of said birefringence layer are oriented according to orientation of photoactive groups in said thin film. Said retardation element is used in a three-dimensional display, and the like.
US6656971B2
申请人:——
公开号:US6656971B2
公开(公告)日:2003-12-02
[EN] TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE<br/>[FR] COMPOSES DE LIAISON DE LA CYCLOPHILINE CARBOXYLIQUE TRISUBSTITUEE ET LEUR UTILISATION
申请人:GUILFORD PHARM INC
公开号:WO2002059080A2
公开(公告)日:2002-08-01
The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins, and to pharmaceutical compositions comprising one or more of the said compounds. The invention further relates to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders.